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Abstract
Mitoferrin1 is 1 of 2 homologous mitochondrial iron transporters
and is required for mitochondrial iron delivery in developing
erythroid cells. We show that total deletion of Mfrn1 in embryos
leads to embryonic lethality. Selective deletion of Mfrn1 in adult
hematopoietic tissues leads to severe anemia because of a
deficit in erythroblast formation. Deletion of Mfrn1 in
hepatocytes has no phenotype or biochemical effect under
normal conditions. In the presence of increased porphyrin
synthesis, however, deletion of Mfrn1 in hepatocytes results in a
decreased ability to convert protoporphyrin IX into heme,
1
leading to protoporphyria, cholestasis, and bridging cirrhosis.
Our results show that the activity of mitoferrin1 is required to
manage an increase in heme synthesis. The data also show that
alterations in heme synthesis within hepatocytes can lead to
protoporphyria and hepatotoxicity.
Introduction
The biosynthesis of heme and iron-sulfur clusters occurs within
mitochondria, and both processes rely on iron as a substrate. Homologous
members of the family of mitochondrial carrier proteins, Mrs3/Mrs4 in
yeast and mitoferrin1 (Mfrn1) and mitoferrin2 (Mfrn2) in vertebrates, have
been implicated in the acquisition of mitochondrial iron. Deletion of the
yeast homologs MRS3 and MRS4 results in mitochondrial iron deficiency
under conditions of limiting iron, suggesting that these transporters are
high-affinity iron transporters.1–3 The loss of Mfrn1 in zebrafish and
developing erythroid cells results in impaired iron delivery and defective
heme synthesis.4 This deficiency cannot be suppressed by ectopic
expression of the homologous Mfrn2. Mfrn2 is functionally homologous to
Mfrn1, as shown by its expression in yeast4 and nonerythroid mammalian
cells.5 The inability of Mfrn2 to suppress the loss of zebrafish Mfrn1 results
from differences in the regulation of the 2 mitoferrins. Transcription of
Mfrn1 is regulated by the GATA1 transcription factor and is increased
during erythropoiesis.4 Further, the stability of Mfrn1 is increased during
erythropoiesis by its binding to ABCB10, protein induction of which is also
increased during erythropoiesis.5,6 Transcripts for Mfrn1 can be found in
nonerythropoietic tissues but at levels lower than Mfrn2, which is
ubiquitously expressed in all tissues.4
2
Support for the tissue-specific expression of Mfrn1 comes from studies of
zebrafish mutants (frascati) and mouse embryos, which contain a gene-trap
cassette in Mfrn1.4 These embryos die early in development at times that
are consistent with the development of RBCs.4 The coincidence of
embryonic lethality and RBC developmental defects suggests a casual
relationship—that death is due to defective hemoglobinization. There are 2
caveats to the interpretation that Mfrn1 expression is specific for RBC
development. First, the gene-trap disruption of Mfrn1 contains the
neomycin-resistance gene and there have been cases where the inclusion of
that gene affects viability. Second, a finding that Mfrn1 is required for
viability because of its role in RBC hemoglobinization does not exclude its
functioning in other tissues. To address the role of Mfrn1 in embryonic
development and organ function, we generated Mfrn1 deletion constructs
that lacked the neomycin gene and, using Cre/Lox technology, examined the
effect of cell-type–specific deletions. We determined that the mortality of
embryos homozygous for a Mfrn1 deletion was not due to the neomycin
construct, but rather could be ascribed to defective hematopoiesis. Deletion
of Mfrn1 in adult hematopoietic progenitors resulted in a severe anemia,
suggesting that lethality was due to defective hematopoiesis. We determined
that the loss of Mfrn1 in hepatocytes had no effect under basal conditions.
In contrast, increased dietary delta aminolevulinic acid (δALA) in
hepatocyte-specific Mfrn1-knockout mice resulted in high levels of
protoporphyrin IX and liver pathology, indicating that in hepatocytes, Mfrn1
may be required under conditions of increased heme synthesis.
Methods
Targeting vector for disruption of the murine Mfrn1 (Slc25a37) gene
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We used the bacterial artificial chromosome clone RPCI23-132H6
(Invitrogen) containing Mfrn1 (Slc25a37) from mouse strain C57Bl/6J. All
PCRs were carried out with Expand High Fidelity PCR (Roche). The
backbone of the targeting vector was the pTK1 vector provided by the
University of Utah transgenic core facilities, which was slightly modified to
contain compatible restriction enzyme sites. The following PCR products
were cloned into the pTK1 vector in this order: the 5′ homologous region (5′
HR) consisting of a 2.1-kb fragment upstream the EcoRV restriction site
located in the intron 1 adjacent to exon 2; a loxP-flippase recognition target
site (FRT)–neomycin-FRT cassette containing a BamHI restriction site; the
820-bp fragment starting at the EcoRV site, spanning exon 2 and ending 305
bp after the end of exon 2 in intron 2; a loxP site; and finally the 3′
homologous region (3′ HR) consisting of a 8.4-kb fragment from 305 bp
after the end of exon 2 and including exon 3, intron 3, and exon 4.
Sequencing of both loxP sites, the FRT-neomycin-FRT cassette, and exons
2, 3, and 4 confirmed the absence of mutations. The targeting vector was
linearized at the end of the 5′ HR by digestion with NotI, electroporated into
G4 embryonic stem (ES) cells, and selected for G418 and ganciclovir
resistance.
Screening of the ES cell clone and genotyping of animals
156 ES cell clones resistant to G418 and ganciclovir were analyzed for
correct homologous recombination by Southern blot and PCR analyses. For
Southern blot analysis, DNA was purified, digested by BamHI, and probed
with a 5′-flanking probe generated as a PCR product using the forward
primer 5′-TGGTTGCCCCAAGTTCTTAC-3′ and the reverse primer 5′-
ATGACAACCAAAGGGACAGC-3′. PCR analyses confirmed the presence
of the loxP-FRT-neomycin-FRT cassette, exon 2, and the second loxP site in
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the recombinant Mfrn1 locus. Cells from a single heterozygous clone were
injected into C57BL/6J-derived blastocysts that were implanted into foster
mothers. Chimeric animals were identified by coat color, and males were
mated with C57BL/6J females to produce mice heterozygous at the Mfrn1
locus. The Mfrn1floxneo offspring were screened by PCR using a forward
primer, Mfrn1-F (5′-CCACAACCCCTTTGTTTCAT-3′), and 2 reverse
primers, Mfrn1-R1 (5′-GCACCGCCTGTGCTCTAGTA-3′), which
hybridizes in the loxP-FRT-neomycin-FRT cassette and generates a 178-bp
product, and Mfrn1-R2 (5′-ACAGCACTTGTGACCCATGC-3′), which
hybridizes in intron 1 near exon 2 and generates a 62-bp wild-type product.
The neomycin-resistance cassette was subsequently excised by
recombination of FRT sites by breeding Mfrn1flox−NEO/+ mice with flp/flp
mice that express Flp recombinase under the Rosa promoter to obtain
heterozygous Mfrn1flox/+animals.
Disruption of the murine Mfrn1 gene
Mfrn1flox/+ male mice were bred with Hprt-Cre female mice expressing Cre
recombinase under the Hprt promoter to excise exon 2 of Mfrn1 at the
zygote stage and produce a global deletion of Mfrn1 in all tissues (Mfrn1+/
− mice). These mice were bred with Tie2-Cre mice (provided by Ann Moon,
University of Utah), alphaMHC-Cre mice (provided by Abel Dale,
University of Utah), Alb-Cre mice (purchased from The Jackson
Laboratory), and Mx-Cre mice (provided by Nancy Andrews, Duke
University, Durham, NC). The background of the Cre mice was C57Bl. The
background of the FLP-expressing mice was a mixture of C57Bl/Sj, but had
been backcrossed to BL6 for at least 3 generations. Mfrn1flox/flox mice were
bred with Mfrn1+/−;Tie2-Cre mice to selectively inactivate the Mfrn1 gene
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in the hematopoietic and endothelial cells, with Mfrn1+/−;αMHC-Cre mice
to inactivate the Mfrn1 gene in the cardiac myocytes, with Mfrn1+/−;Alb-
Cre mice to inactivate the Mfrn1 gene in the hepatocytes, or with Mfrn1+/
−;Mx-Cre mice to inactivate the Mfrn1 gene mainly in the liver, spleen, and
bone marrow and partially in other tissues.7 Mfrn1+/−;Mx-Cre mice
received 3 IP injections of 250 μg each of poly(I:C) for 5 days every 2 days
to activate the Mx promoter, and were studied at least 3 days after the last
injection. Tail DNA was subjected to PCR for genotyping. We used primers
Mfrn1-F (as in the preceding paragraph), reverse primer Mfrn1-R3 (5′-
AACCCCTCCTTAACCTTGGA-3′), which hybridizes in intron 1 near exon
2 and gives a 173-bp product with a wild-type allele and a 273-bp product
with the floxed allele, and primer Mfrn1-R4 (5′-
GTCTCCGGCAGCTTAAAGTG-3′), which hybridizes in intron 2 near exon
3 and gives a 428-bp product for the negative allele.
Animals
All procedures involving animals were approved by the University of Utah
Animal Care Committee. All mice were born and housed in the University
of Utah transgenic facility or mouse house facility. Mice were maintained
on a standard rodent diet that included 350 parts per million of iron. Mice
were given drinking water supplemented with 2 mg/mL of δ-ALA to bypass
the rate-limiting step in hepatic porphyrin synthesis (ALA-synthase 1), as
described previously.8 In all experiments, littermates from the same
breeding pair were used as controls.
TAT-Cre transduction
Skin fibroblasts were isolated from Mfrn1flox/− and Mfrn1+/− mice and
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transduced with recombinant TAT-Cre proteins (kindly provided by Dr Matt
Hockin, University of Utah) for 2 hours. Sixteen hours later, the cells were
exposed to 2 mg/mL of ALA in culture medium for 8 hours, and analyzed
for protoporphyrin IX content and Cre-mediated recombination.
Protoporphyrin IX and Zn-protoporphyrin measurements
Liver was homogenized at 100 mg/mL in 10mM Tris-HCl, pH 7.0. For total
protoporphyrin IX measurement, lysates were extracted with ethyl acetate
and acetic acid (4:1) and centrifuged for 15 minutes at 1500 rpm to remove
precipitated proteins. Protoporphyrin IX was extracted in 1.5N HCl and
measured in a spectrofluorometer at a 405-nm excitation wavelength and a
604-nm emission wavelength. Total serum protoporphyrin IX and washed
erythrocyte protoporphyrin IX analyses were performed as described for
liver total protoporphyrin IX analysis without the homogenizing step.
Erythrocyte protoporphyrin was expressed as concentration per liter of
packed cells. For Zn-protoporphyrin IX measurement, liver lysates were
extracted with ethanol. The extracts were measured in a spectrofluorometer
at a 415-nm excitation wavelength and a 589-nm (Zn-protoporphyrin) or
632-nm (protoporphyrin IX) emission wavelength. Protoporphyrin standards
were purchased from Porphyrin Products.
Other procedures
Blood was collected from anesthetized animals by heart puncture into
heparinized tubes. Hematocrit, hemoglobin, RBC numbers, and mean
corpuscular volume (MCV) were measured. Hematoxylin-eosin and
trichrome staining were performed by ALM Laboratories. Western blots
were developed using Western Lightning reagent (Perkin-Elmer). Aconitase
was assayed as described previously.2 A xanthine oxidase assay was carried
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out on liver lysates using the Amplex Red Xanthine Oxidase Assay Kit
(Invitrogen) following the manufacturer's instructions. Ferrochelatase was
assayed by a modification of the method used by Sellers and Dailey.9
Briefly, enzyme activity was determined by measuring the absorbance at
550 nm over time from a reaction mixture containing 1mM
deuteroporphyrin, 50μM NiCl2, and the lysate of freshly isolated
mitochondria. Respiratory complex activity was assayed as described by
Barrientos,10 and the assay for malate dehydrogenase can be found at:
https://www.mnstate.edu/provost/MDHAssayProtocol.pdf.
RT-PCR
For gene amplification, 50 ng of mRNA was used for quantitative RT-PCR
using the One-Step qRT-PCR kit according to the manufacturer's
instructions (Invitrogen). The primers used amplified a sequence in exon 1
(F-ACGAGAACCTACCGACCAGC) and exon 4 (R-
GGCACGCAGGGTAACTGTAT). A wild-type mRNA gives rise to a
transcript amplification of 443 bp; a deletion of exon 2 at the genomic level
gives rise to a transcript amplification of 214 bp.
Results
Targeted disruption of Mfrn1
The murine Mfrn1 (Slc25a37) gene consists of 4 exons spread over more
than 43 kb on mouse chromosome 14 on the reverse strand, with exon 1 far
from the other 3 (Figure 1A). We designed a targeting construct in which
coding exon 2 was flanked with loxP sites. The neomycin-resistance gene,
flanked with FRT sites to permit its excision, was inserted in the first intron
(Figure 1B). This construct was introduced by electroporation into mouse
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G4 ES cells (C57BL6/129 hybrid). Homologous recombination was
confirmed by Southern blot analysis (Figure 1E) and PCR analysis. ES cells
carrying the Mfrn1floxneo allele were injected into blastocysts to generate
germline chimeric animals (Figure 1F). The neomycin cassette in the
targeting construct, which was flanked with FRT sites, was removed by
crossing heterozygous Mfrn1+/neo with flp recombinase mice to produce
mice carrying the Mfrn1flox allele (Figure 1C,G). Deletion of exon 2 was
produced by a cross of Mfrn1flox/+ mice with zygote-expressing Cre
recombinase mice to produce Mfrn1+/− mice (Figure 1D,G). Mice were
maintained on a C57BL/6 background and Mfrn1+/− mice appeared normal.
Mice homozygous for Mfrn1flox/− showed no anatomical abnormalities (eg,
in size or weight), hematologic parameters, or plasma and liver porphyrin
concentration abnormalities compared with wild-type littermates (data not
shown).
9
View larger version
Figure 1. Generation of floxed Mfrn1 alleles. Schematic
description of the wild-type Mfrn1 locus (A) and the locus after
introduction of a loxP-FRT-neomycin resistance-FRT cassette in
intron 1 and an additional loxP site between exons 2 and 3 (B). The
position of the 5′-flanking probe used for Southern blot analysis is
shown as a blue bar in panels A and B. (C) Flp recombinase–mediated excision in
which the neomycin cassette was removed by FRT recombination but the coding
sequence was left intact. (D) Complete Cre recombinase–mediated excision of exon
2 to inactivate the Mfrn1 gene. For panels A through D, LoxP sites are shown as red
triangles and FRT sites are shown as green diamonds. (E) Southern blot analysis of
the 5′ end of the locus in ES cells after BamHI digestion. Lane 1 shows the wild-type
allele at 7.4 kb, and lanes 2-4 targeted recombination with a wild-type allele at 7.4 kb
and a recombinant allele at 4.5 kb, as indicated in panels A and B. (F) PCR analysis
of the offspring of Mfrn1floxneo/+ and Mfrn1+/+ chimeric mice. PCR was done using
primers F, R1, and R2, as indicated in panels A and B. Lane 1 and lane 4 show the
Mfrn1floxneo/+ genotype and lanes 2 and 3 the Mfrn1+/+ genotype. The presence of
Neo (primers F × R1) gives a product of 120 bp; the absence of Neo (primers F × R2)
gives a product of 60 bp. (G) PCR analysis of Cre recombinase–mediated excision of
exon 2. PCR was done using primers F, R3, and R4, as indicated in panels C and D.
The wild-type allele gives a product of 173 bp (primers F × R3), the flox allele gives a
product of 273 bp (primers F × R3), the negative allele gives a product of 428 bp
(primers F × R4), and R3 does not hybridize anymore. Lane 1 shows the Mfrn1flox/−
genotype, lane 2 shows the Mfrn1+/− genotype, lanes 3 and 4 show the Mfrn1flox/+
genotype, and lane 5 shows the Mfrn1+/+ genotype.
Embryonic lethality of Mfrn1−/− mice
Crossing mice heterozygous for a Mfrn1 deletion (Mfrn1+/−) in all tissues
did not yield any live Mfrn1−/− animals. Mendelian ratios of littermate
genotypes indicated that Mfrn1−/− mice died prenatally (64 pups analyzed;
Table 1). Analysis of embryos showed that embryonic lethality in Mfrn1−/−
mice occurred between embryonic day 9.5 (E9.5) and E11.5. Inactivation of
Mfrn1 in embryos was confirmed by PCR analysis (Figure 2A) and Western
blot analysis (Figure 2B). The removal of exon 2 in the Mfrn1 locus leads to
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the expression of a shorter mRNA, but does not result in the accumulation
of the Mfrn1 protein. Compared with wild-type embryos at E9.5 (Figure
2C,E,G), Mfrn1−/− embryos were noticeably paler (Figure 2D,F,H), with an
absence of hemoglobinization in the yolk sac and heart. Mfrn1−/− embryos
were not found after E11.5. These data demonstrate that it is the deletion of
Mfrn1 and not the expression of the neomycin-resistance gene that leads to
embryonic lethality
See full table
Table 1. Embryonic lethality of due to deletion of
Mfrn1
View larger version
Figure 2. Embryonic lethality of a homozygous Mfrn1
deletion. (A) PCR analysis of the offspring from the breeding of
Mfrn1+/− with Mfrn1+/− mice. These littermates were genotyped at
E9.5. In this particular litter, 1 animal was wild-type, 6 were
heterozygous, and 1 was homozygous for the Mfrn1 deletion. PCR
was done using primers F, R3, and R4, as indicated in the legend to
Figure 1. (B) Western blot of whole embryos probed with antibodies
against Mfrn1, Mfrn2, and tubulin using peroxidase-conjugated goat
anti–rabbit IgG or goat anti–mouse IgG. (C-H) Stereomicroscopy of
E9.5 embryos from Mfrn1+/− × Mfrn1+/− breeding. Panels C, E, and G are the Mfrn1+/
− mouse; panels D, F, and H are the Mfrn1−/− mouse. Panels C and D show embryos
kept in the yolk sac, panels E and F show embryos without their yolk sac, and panels
G and H are enlarged images from panels E and F. The Mfrn1−/− mouse is deprived
of hemoglobin, as shown by the lack of RBCs in vasculature of the yolk sac (ys) in
panel D compared with panel C, and by the hemoglobinization of the heart and the
common atrial chamber of the heart (h) in panels F and H compared with Mfrn1+/−
mice panels E and G.
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To investigate the mechanism underlying embryonic lethality, we targeted
the disruption of Mfrn1 in endothelial and hematopoietic cells using Tie2-
Cre mice. Tie2-Cre is active in blood islands, aorta-gonad-mesonephros
region, and endothelial cells starting at E7.5 and E8.5, and fetal liver
hematopoietic cells and in circulating blood cells starting at E11.5.11 No
live Tie2-Cre;Mfrn1flox/− pups were identified in more than 50 pups
analyzed (data not shown). Because Mfrn1 is also expressed in the
developing heart, we used a cardiac-specific Cre, αMHC-Cre, to determine
whether Mfrn1 expression in that tissue was critical for early development.
Cre expression is under the regulation of the αMHC promoter, which is
expressed in cardiac myocytes starting at E9.5. αMHC-Cre, Mfrn1-deleted
mice were viable and showed no phenotype up to 3 months of birth. A cross
between αMHC-Cre and ROSA-LacZ mice showed that the αMHC-Cre was
expressed and functional in cardiomyocytes (supplemental Figure 1,
available on the Blood Web site; see the Supplemental Materials link at the
top of the online article). It is possible that loss of Mfrn1 in the Tie2-
Cre;Mfrn1flox/− pups resulted in the dysfunction of multiple tissues, but the
data are consistent in showing that it is the disruption of Mfrn1 in
endothelial and/or hematopoietic cells at the early stage of development and
not in cardiac myocytes that is responsible for embryonic lethality of
Mfrn1−/− animals.
Mice with an induced deletion of Mfrn1 develop anemia
To assess the role of Mfrn1 in definitive (adult) RBC development, we used
a hematopoietic Cre construct that was inducible after birth. We crossed the
Mfrn1flox/− allele into mice carrying an inducible Mx-Cre, which is
expressed in hematopoietic tissue. Four weeks after birth, we exposed
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Mfrn1flox/−;Mx-Cre mice to poly(I:C), which induces expression of Cre in
most cell types, including hematopoietic precursors. Examination 4 weeks
later showed that there was a significant loss of Mfrn1 in the spleen, liver,
and bone marrow in Mfrn1flox/−;Mx-Cre animals exposed to the poly(I:C)
inducer (Figure 3A-B). Animals not exposed to poly(I:C) showed no loss of
the Mfrn1flox/− allele. Western analysis of mitochondria obtained from
bone marrow or splenic cells showed a marked loss of Mfrn1 (Figure 3C).
These results show an efficient deletion of Mfrn1 in erythropoietic tissues.
View larger version
Figure 3. Deletion of Mfrn1 in adult mice leads to loss of
Mfrn1 in hematopoietic tissues. Mfrn1flox/− mice were crossed to
mice carrying Mx-Cre. At 3 weeks of age, mice (Mfrn1flox/−;Mx-Cre)
were injected with poly(I:C) to induce Cre expression. The mice were
analyzed 4-8 weeks later. (A) PCR analysis of Mfrn1 of genomic
DNA from thymus (T), spleen (S), liver (L), and bone marrow (Bm) of
mice with noted genotypes. (B) RT-PCR analysis of mRNA in the spleens of mice with
the noted genotypes using primers specific to exon1 and exon4, which flank exon 2. A
wild-type mRNA gave rise to a transcript amplification of 443 bp; a deletion of exon 2
at genomic level gave rise to a transcript amplification of 214 bp. (C) Western analysis
of Mfrn1, porin, and tubulin in cytosol, mitochondria, and total bone marrow isolated
from mice with the specified genotypes. (D) Bar graph of spleen weight/total weight of
mice with the noted genotypes. (E). Hematoxylin and eosin–stained sections of spleen
from Mfrn1+/+ mice and Mx-Cre–deleted Mfrn1−/− mice.
Analysis of bone marrow and spleen showed evidence of ineffective
erythropoiesis with compensatory splenic hematopoiesis. Spleens were
greatly enlarged (Figure 3D) and showed a marked change in architecture
that is suggestive of increased erythropoiesis (Figure 3E). After induction
by poly(I:C), there was a time-dependent change in RBC number in mice
carrying the Mfrn1flox/−;Mx-Cre allele, but no significant changes in these
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hematologic parameters were observed in control Mx-Cre mice. Poly(I:C)–
treated Mfrn1flox/−;Mx-Cre mice developed anemia, as shown by the
decrease in hemoglobin concentration (Figure 4A), RBC number (Figure
4B), hematocrit (Figure 4C), and MCV (Figure 4D). FACS analysis of
erythroid cells from poly(I:C)–treated Mfrn1flox/−;Mx-Cre mice showed a
marked increase in erythroblasts, which represented 69% ± 4% (mean ±
SEM; n = 6) of splenocytes compared with 1.9% ± 0.5% (n = 9) in
poly(I:C)–treated control mice (Figure 4E-I). Splenic erythroid progenitor
cells were increased by 5-fold, whereas T- and B-cell frequencies were
markedly reduced (by 4-fold and 6-fold, respectively), possibly because of
the relative increase in erythroblasts (data not shown). Splenic myeloid cell
frequency, however, was not altered. Analysis of bone marrow showed
normal numbers of cells with several notable differences in cellular
distribution. The erythroblast compartment was increased by 2-fold in the
deleted mice, whereas mature erythrocytes numbered 50% of control levels,
which is consistent with compensatory erythropoiesis due to peripheral
anemia (data not shown). Our data show that the terminal stages of
erythropoiesis (TER-119+) are largely similar between control and
mitoferrin 1–knockout mice, with some differences in the intensity of
staining because TER-119 levels were lower and CD71 levels were higher in
the knockout mice (Figure 4F). However, the early stages of erythropoiesis
(TER-119−) were markedly distinct, with the knockout mice exhibiting a
10-fold increase in early erythroid progenitors (CD71+TER-119−). The data
indicate that the distribution of progenitors within the TER-119− progenitor
compartment with respect to CD71 and c-kit (Figure 4G) showed a 10-fold
increase in primitive erythroid progenitors, which includes both c-kit+ and
c-kit− progenitors. The frequency of nonviable cells was increased by an
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average of 2- to 3-fold in both spleen and bone marrow (Figure 4H). These
results confirm that Mfrn1 is essential for hemoglobinization in developing
adult erythrocytes. The frequency of B-lineage cells in bone marrow was
reduced 4-fold, with no reduction in myeloid cell frequency (Figure 4I).
Coupled with the decrease in splenic B-cell frequency, this result suggests
that Mfrn1 may also play an important role in B-cell development.
View larger version
Figure 4. Changes in hematologic values after deletion of
Mfrn1 in MX-Cre mice. Mice with the noted genotypes were
injected with poly(I:C) to induce Cre recombinase. At times
subsequent to induction of Cre, blood was taken for analysis of
hemoglobin (HGB; A), RBC number (B), hematocrit (C), and MCV
(D). Flow cytometric analysis of hematopoiesis in Mfrn1-knockout
mice. Groups of Mx-Cre (Control) or floxed Mfrn1/Mx-Cre mice were treated with
poly(I:C) and killed 8 weeks later for analysis of hematopoietic tissues. (E) Spleen cell
suspensions were treated with ammonium chloride to lyse mature erythrocytes and
evaluated for expression of the erythroid marker TER-119, which indicates erythroblast
cells. (F-I) Bone marrow cell suspensions were isolated and evaluated for
hematopoietic markers as indicated. (F) Selective gating for the hematopoietic stem
and progenitor cell compartment (viable cells lacking expression of the lineage
markers B220 and CD11b). Mfrn1-deleted mice exhibited increased numbers of
erythroid progenitor cells (CD71+TER-119−). (G) Selective gating to exclude B220,
CD11b, and TER-119+ cells. It can be seen that Mfrn1-deleted mice exhibit an
increase in erythroid progenitor cells (c-kit+CD71+) and proerythroblasts (c-kit
−CD71+). We also observed increased numbers of nonviable CD71+ cells
(DAPI+CD71+; H) and decreased numbers of B-lineage cells based on B220
expression (I) in Mfrn1-deleted mice. Panels are representative of 6 Mfrn1-deleted
mice and 9 control animals.
Targeted disruption of the Mfrn1 gene in hepatocytes
To determine whether there is a role for Mfrn1 in tissues other than
hematopoietic cells, we focused on hepatocytes because these cells show a
high demand for heme. Mfrn1flox/− mice were crossed with mice containing
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an integrated Cre gene driven by the albumin promoter (Alb-Cre). To
confirm that Alb-Cre was expressed and functional, we crossed Alb-Cre
mice with Rosa-LacZ mice and examined the livers and spleens for the
expression of β-galactosidase. No expression of β-galactosidase was seen in
the spleens of Alb-Cre;Rosa-LacZ mice, whereas abundant β-galactosidase
activity was seen in the hepatocytes of these mice (supplemental Figure
2A). We note that the deletion was not complete, perhaps reflecting the
presence of nonhepatocyte cell types in the liver. We checked the efficacy
of disruption by PCR analysis of genomic DNA from the livers of
Mfrn1flox/− and Alb-Cre;Mfrn1flox/− mice (supplemental Figure 2B), and
were able to demonstrate reduced levels of the floxed allele of Mfrn1 due to
Alb-Cre. Examination of mRNA by RT-PCR using primers specific for
Mfrn1 mRNA exon1 and exon 4 showed the appearance of the mRNA
lacking exon 2 in the liver of an Alb-Cre;Mfrn1flox/− mouse compared with
the spleen from the same animal (supplemental Figure 2C). The level of
Mfrn1 protein in normal liver was too low to be detected by Western blots
using the current antibodies. Loss of Mfrn1, however, did not affect the
level of Mfrn2 mRNA or Mfrn2 protein (supplemental Figure 2D). The loss
of Mfrn1 in hepatocytes had no effect on viability or on other measured
parameters of iron and heme metabolism (data not shown).
We next examined whether there was a role for Mfrn1 under conditions of
increased heme synthesis. Mice were given ALA in their drinking water for
4 weeks. ALA bypasses the rate-limiting step in porphyrin biosynthesis and
is expected to lead to increased porphyrin synthesis. Wild-type mice fed
ALA showed little evidence of increased porphyrin intermediates in the
urine, liver, or blood. In contrast, higher levels of protoporphyrin IX were
seen in the plasma (Figure 5A), liver (Figure 5B), and RBCs (Figure 5C) of
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ALA-fed Alb-Cre;Mfrn1flox/− mice. Mice heterozygous for hepatocyte
Mfrn1 (Alb-Cre;Mfrn1flox/+) also had higher levels of protoporphyrin than
control mice but lower levels than homozygous deleted mice. Iron
deficiency often leads to increased levels of Zn-protoporphyrin,12 but we
did not observe increased Zn-protoporphyrin in tissue, RBCs, or plasma
(data not shown). Further, we did not observe significant changes in the
activity of the cytosolic iron-sulfur cluster–containing enzyme xanthine
oxidase, the mitochondrial iron-sulfur–containing succinate dehydrogenase
or ferrochelatase, respiratory complex III, or the heme-containing
respiratory complex IV (supplemental Figures 3-4). The changes in the
activities of these enzymes were minimal and were on the same order of
magnitude as changes in the activity of the iron-free mitochondrial enzyme
malate dehydrogenase. We did observe changes in the activities of
mitochondrial and cytosolic aconitase. The fact that the activity of other
mitochondrial and cytosolic iron-sulfur–containing enzymes were not
altered suggests that, in general, the synthesis of iron-sulfur clusters was not
affected by the loss of Mfrn1 in hepatocytes.
View larger version
Figure 5. Deletion of Mfrn1 in hepatocytes leads to
increased protoporphyrin IX in mice fed ALA. ALA was added to
the drinking water of mice of the noted genotypes. Four weeks later,
the ALA-fed mice and control mice were killed and the level of
protoporphyrin IX (PPIX) measured in plasma (A), liver (B), and
erythrocytes (C). (D) PCR analysis of Mfrn1 deletion in fibroblasts
incubated with Tat-Cre. (E) Levels of PPIX in wild-type and Mfrn1-deleted fibroblasts.
*P < .05.
We confirmed that the increase in protoporphyrin IX was the result of
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decreased expression of Mfrn1. Cultured fibroblasts from Mfrn1flox/− mice
were incubated with TAT-Cre, which induced loss of the floxed allele in
greater than 90% of cultured cells (Figure 5D). The addition of ALA to wild-
type or Mfrn1flox/− cells did not lead to increased protoporphyrin IX levels
(Figure 5E). In contrast, incubation of Tat-Cre–treated Mfrn1flox/− cells
with ALA led to a 4-fold increase in protoporphyrin IX levels.
Deletion of hepatocyte Mfrn1 in ALA-fed animals results in
hepatotoxicity
We noted that deletion of hepatocyte Mfrn1 in ALA-fed animals affected
the size of the liver. There was no difference in liver size between wild-type
animals and hepatocyte Mfrn1-deleted animals in the absence of added ALA
(Figure 6A). Further, ALA feeding had no effect on liver weight in wild-
type animals compared with wild-type animals not fed ALA. In contrast,
ALA-fed animals showed an increase in liver size that was graded with the
loss of Mfrn1, because the homozygous deletion showed a greater effect
than the heterozygous deletion. We also noted a small increase in spleen
size in homozygous Mfrn1 hepatocyte–deleted animals fed ALA (Figure
6B).
View larger version
Figure 6. Hepatotoxicity in livers of hepatocyte-deleted
Mfrn1 animals fed ALA. ALA was added to the drinking water of
mice of the noted genotypes (Mfrn1+/+, Mfrn1flox/+, and Alb-
Cre;Mfrn1flox/−). Four weeks later, the ALA-fed mice and control
mice were killed and liver weight/body weight (A) and spleen
weight/body weight (B) were determined. *P < .05.
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Histochemical analysis of the livers from ALA-fed, hepatocyte-deleted
(Alb-Cre;Mfrn1flox/−) mice revealed pathologic changes that were not seen
in either ALA-fed normal mice (Figure 7) or hepatocytes of Alb-
Cre;Mfrn1flox/− mice not fed ALA (data not shown). Most notably was the
presence of increased collagen deposition in the Alb-Cre;Mfrn1flox/+
heterozygotes and the Alb-Cre;Mfrn1flox/− homozygous mouse livers.
Livers from heterozygous mice showed bile duct proliferation in the
periportal area and chronic periportal inflammation. A brown pigment was
also seen in the bile ducts of the ALA-fed Alb-Cre;Mfrn1flox/− mice that
was not seen in normal animals fed ALA. This pigment was consistent with
accumulated bile, suggesting cholestasis. Heterozygous mice showed a
chronic cholestatic pattern and early fibrosis compared with wild-type mice.
The homozygous mice showed a more severe pattern with a more reactive
epithelium and lymphocytes in the lobule area. Fibrosis was also more
developed, bridging periportal and centrolobular areas and starting to form
nodules.
View larger version
Figure 7. Histochemical analysis of wild-type and
hepatocyte-deleted Mfrn1 livers. Livers from mice fed ALA were
harvested at 6 weeks and stained with hematoxylin and eosin (A) or trichrome (B) in
Alb-Cre;Mfrn1+/+. (C) Enlarged image from panel B. Alb-Cre;Mfrn1flox/+ were stained
with hematoxylin and eosin (D) or trichrome (E). Panel F is an enlarged image from
panel E. Alb-Cre;Mfrnlflox/− were stained with hematoxylin and eosin (G) or trichrome
(H). Panel I is an enlarged image from panel G. Asterisks in the enlarged images of
panels F and I denote areas of fibrosis.
Discussion
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Previous studies and those reported here show that Mfrn1 is essential for
heme synthesis in developing erythroid cells.4,5 The loss of Mfrn1 in mouse
embryos results in lethality and, as shown here, the loss of Mfrn1 in adults
results in severe anemia. Our data show that it is the specific loss of Mfrn1
in erythroid cells that leads to anemia, because deletion of Mfrn1 in
(definitive) hematopoietic stem cells in adult mice resulted in a severe
anemia. Our data also indicate a decrement in the number of B cells,
suggesting that Mfrn1 may play a role in B-cell lineage development.
Studies are ongoing to test that hypothesis.
We then focused on the effect of deletion of Mfrn1 in hepatocytes because
these cells have a high demand for heme due to the synthesis of heme
containing P450. The original description of mitoferrins showed that Mfrn1
was expressed in hepatocytes, although (on the mRNA level) to a lesser
extent than Mfrn2. Loss of hepatocyte Mfrn1 has no consequences either in
terms of protoporphyrin accumulation or pathology in mice maintained on
standard laboratory diets. In developing erythroid cells, the turnover rate of
Mfrn1 is affected by the presence of Abcb10, which stabilizes Mfrn1 and
increases its half-life. There is also evidence of Abcb10 transcripts in the
liver, although it is not clear whether Abcb10 has an effect on hepatocyte
Mfrn1 turnover.13 The deletion of Mfrn1 does not affect the level of Mfrn2
transcripts, which do not interact with Abcb10.6
Changes in pathology and porphyrin levels were only seen when porphyrin
synthesis was increased in hepatocyte Mfrn1–deleted mice. Under these
conditions, the hepatocyte Mfrn1–deleted mice showed a liver phenotype
indistinguishable from erythrocyte protoporphyria (EPP), with increased
protoporphyrin IX and a liver pathology of bridging cirrhosis with apparent
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cholestasis. EPP most commonly results from mutations in ferrochelatase,
the enzyme that catalyzes the final step in the heme-biosynthetic pathway.
Decreased ferrochelatase activity would result in decreased iron insertion
into the protoporphyrin IX macrocycle, leading to the increased
accumulation of protoporphyrin IX. Thus, conditions that result in a relative
increase in porphyrin synthesis relative to the ability to insert iron into the
porphyrin ring would result in increased protoporphyrin IX levels. Such
conditions include the increased expression of ALA synthase due to
homozygous deletions in mouse IRP214 or mutations in the carboxyl-
terminal end of ALA synthase, which modulates enzyme activity.15 In mice
with mutations in ferrochelatase16,17 or a deletion in IRP2,14 increased
levels of protoporphyrin IX result predominately from increased
protoporphyrin synthesis in erythrocytes. When normal bone marrow is
transplanted into ferrochelatase mutant mice, the ferrochelatase defect is
retained in liver cells. In all existing models of EPP, defects in either
ferrochelatase activity or ALA synthase are the most predominant in the
erythroid lineage, although ferrochelatase deficiencies are expressed in
erythroid precursors and in the liver. Bone marrow transplantation
“normalizes” erythroid ferrochelatase activity but not hepatocyte
ferrochelatase activity. It is unclear whether the liver pathology seen in
transplanted mouse EPP models reflects preexisting pathology or pathology
due to the continued production of protoporphyrin IX by the defective liver
enzyme.18
As shown here, decreased hepatocyte Mfrn1 levels lead to increased
protoporphyrin IX when heme synthesis is expanded by addition of ALA.
The finding that protoporphyrin IX levels increase indicates that Mfrn2-
mediated iron delivery is not sufficient to accommodate the increase in
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porphyrin demand. This result confirms studies in cultured cells using RNA
interference to lower the levels of Mfrn1 or Mfrn2.5 Reduction in either
Mfrn1 or Mfrn2 had no effect on heme synthesis or porphyrin accumulation
under normal conditions. In the presence of ALA, depletion of Mfrn1 or
Mfrn2 resulted in increased protoporphyrin IX, indicating that
mitochondrial iron delivery was insufficient to catalyze iron incorporation
into the porphyrin macrocycle. The expression of Mfrn2 in Mfrn1-silenced
cells or vice versa normalized protoporphyrin levels, indicating that the
accumulation of protoporphyrin IX was due to iron limitation into
mitochondria. These findings indicate that the activity or level of Mfrn2
cannot increase in response to heme demand or Mfrn1 deficiency.
Our most striking finding was the appearance of liver fibrosis and cirrhosis
that were dependent on the copy level of Mfrn1, with heterozygotes and
homozygotes showing pathology and normal mice not showing pathology.
Mutations in ferrochelatase affect the enzyme in both hepatocyte and
erythroid precursors, leading to protoporphyria and liver pathology.
Reconstitution of normal bone marrow in mutant animals did not
completely suppress liver pathology. Bone marrow transplantation, while
robust (90%), was not complete, and the failure to suppress cirrhosis might
reflect protoporphyrin IX generation by hepatocytes and/or by the residual
host mutant RBCs. The results presented here show that defects in
hepatocyte porphyrin production can itself lead to hepatic toxicity,
suggesting that liver-specific defects can result in protoporphyria.
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Figure 1.
Generation of floxed Mfrn1 alleles. Schematic description of the wild-type Mfrn1
locus (A) and the locus after introduction of a loxP-FRT-neomycin resistance-FRT
cassette in intron 1 and an additional loxP site between exons 2 and 3 (B). The
position of the 5′-flanking probe used for Southern blot analysis is shown as a blue
bar in panels A and B. (C) Flp recombinase–mediated excision in which the
neomycin cassette was removed by FRT recombination but the coding sequence
was left intact. (D) Complete Cre recombinase–mediated excision of exon 2 to
inactivate the Mfrn1 gene. For panels A through D, LoxP sites are shown as red
triangles and FRT sites are shown as green diamonds. (E) Southern blot analysis of
the 5′ end of the locus in ES cells after BamHI digestion. Lane 1 shows the wild-type
allele at 7.4 kb, and lanes 2-4 targeted recombination with a wild-type allele at 7.4 kb
and a recombinant allele at 4.5 kb, as indicated in panels A and B. (F) PCR analysis
of the offspring of Mfrn1floxneo/+ and Mfrn1+/+ chimeric mice. PCR was done using
primers F, R1, and R2, as indicated in panels A and B. Lane 1 and lane 4 show the
Mfrn1floxneo/+ genotype and lanes 2 and 3 the Mfrn1+/+ genotype. The presence of
Neo (primers F × R1) gives a product of 120 bp; the absence of Neo (primers F ×
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R2) gives a product of 60 bp. (G) PCR analysis of Cre recombinase–mediated
excision of exon 2. PCR was done using primers F, R3, and R4, as indicated in
panels C and D. The wild-type allele gives a product of 173 bp (primers F × R3), the
flox allele gives a product of 273 bp (primers F × R3), the negative allele gives a
product of 428 bp (primers F × R4), and R3 does not hybridize anymore. Lane 1
shows the Mfrn1flox/− genotype, lane 2 shows the Mfrn1+/− genotype, lanes 3 and 4
show the Mfrn1flox/+ genotype, and lane 5 shows the Mfrn1+/+ genotype.
[Back]
28
[Back]
Table 1.
Embryonic lethality of due to deletion of Mfrn1
Embryos/pups
≤ E9.5 (n =
37)
≥ E11.5 (n =
41)
Newborn (n =
64)
Mfrn1 +/+ 10 10 20
Mfrn1 +/− 19 22 44
Mfrn1 −/− 8 0 0
Not determined (necrotic
embryos)
0 9 0
Mice (Mfrn1+/−) heterozygous for a Mfrn1 deletion were intercrossed and the progeny were
genotyped.
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29
[Back]
30
31
Figure 2.
Embryonic lethality of a homozygous Mfrn1 deletion. (A) PCR analysis of the
offspring from the breeding of Mfrn1+/− with Mfrn1+/− mice. These littermates were
genotyped at E9.5. In this particular litter, 1 animal was wild-type, 6 were
heterozygous, and 1 was homozygous for the Mfrn1 deletion. PCR was done using
primers F, R3, and R4, as indicated in the legend to Figure 1. (B) Western blot of
whole embryos probed with antibodies against Mfrn1, Mfrn2, and tubulin using
peroxidase-conjugated goat anti–rabbit IgG or goat anti–mouse IgG. (C-H)
Stereomicroscopy of E9.5 embryos from Mfrn1+/− × Mfrn1+/− breeding. Panels C,
E, and G are the Mfrn1+/− mouse; panels D, F, and H are the Mfrn1−/− mouse.
Panels C and D show embryos kept in the yolk sac, panels E and F show embryos
without their yolk sac, and panels G and H are enlarged images from panels E and F.
The Mfrn1−/− mouse is deprived of hemoglobin, as shown by the lack of RBCs in
vasculature of the yolk sac (ys) in panel D compared with panel C, and by the
hemoglobinization of the heart and the common atrial chamber of the heart (h) in
panels F and H compared with Mfrn1+/− mice panels E and G.
[Back]
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Figure 3.
Deletion of Mfrn1 in adult mice leads to loss of Mfrn1 in hematopoietic
tissues. Mfrn1flox/− mice were crossed to mice carrying Mx-Cre. At 3 weeks of age,
mice (Mfrn1flox/−;Mx-Cre) were injected with poly(I:C) to induce Cre expression. The
mice were analyzed 4-8 weeks later. (A) PCR analysis of Mfrn1 of genomic DNA
from thymus (T), spleen (S), liver (L), and bone marrow (Bm) of mice with noted
genotypes. (B) RT-PCR analysis of mRNA in the spleens of mice with the noted
genotypes using primers specific to exon1 and exon4, which flank exon 2. A wild-
type mRNA gave rise to a transcript amplification of 443 bp; a deletion of exon 2 at
genomic level gave rise to a transcript amplification of 214 bp. (C) Western analysis
of Mfrn1, porin, and tubulin in cytosol, mitochondria, and total bone marrow isolated
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from mice with the specified genotypes. (D) Bar graph of spleen weight/total weight
of mice with the noted genotypes. (E). Hematoxylin and eosin–stained sections of
spleen from Mfrn1+/+ mice and Mx-Cre–deleted Mfrn1−/− mice.
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Figure 4.
Changes in hematologic values after deletion of Mfrn1 in MX-Cre mice. Mice
with the noted genotypes were injected with poly(I:C) to induce Cre recombinase. At
times subsequent to induction of Cre, blood was taken for analysis of hemoglobin
(HGB; A), RBC number (B), hematocrit (C), and MCV (D). Flow cytometric analysis
of hematopoiesis in Mfrn1-knockout mice. Groups of Mx-Cre (Control) or floxed
Mfrn1/Mx-Cre mice were treated with poly(I:C) and killed 8 weeks later for analysis
of hematopoietic tissues. (E) Spleen cell suspensions were treated with ammonium
chloride to lyse mature erythrocytes and evaluated for expression of the erythroid
marker TER-119, which indicates erythroblast cells. (F-I) Bone marrow cell
suspensions were isolated and evaluated for hematopoietic markers as indicated.
(F) Selective gating for the hematopoietic stem and progenitor cell compartment
(viable cells lacking expression of the lineage markers B220 and CD11b). Mfrn1-
deleted mice exhibited increased numbers of erythroid progenitor cells (CD71+TER-
119−). (G) Selective gating to exclude B220, CD11b, and TER-119+ cells. It can be
seen that Mfrn1-deleted mice exhibit an increase in erythroid progenitor cells (c-
kit+CD71+) and proerythroblasts (c-kit−CD71+). We also observed increased
numbers of nonviable CD71+ cells (DAPI+CD71+; H) and decreased numbers of B-
lineage cells based on B220 expression (I) in Mfrn1-deleted mice. Panels are
representative of 6 Mfrn1-deleted mice and 9 control animals.
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Figure 5.
Deletion of Mfrn1 in hepatocytes leads to increased protoporphyrin IX in
mice fed ALA. ALA was added to the drinking water of mice of the noted genotypes.
Four weeks later, the ALA-fed mice and control mice were killed and the level of
protoporphyrin IX (PPIX) measured in plasma (A), liver (B), and erythrocytes (C). (D)
PCR analysis of Mfrn1 deletion in fibroblasts incubated with Tat-Cre. (E) Levels of
PPIX in wild-type and Mfrn1-deleted fibroblasts. *P < .05.
[Back]
37
[Back]
Figure 6.
Hepatotoxicity in livers of hepatocyte-deleted Mfrn1 animals fed ALA. ALA
was added to the drinking water of mice of the noted genotypes (Mfrn1+/+,
Mfrn1flox/+, and Alb-Cre;Mfrn1flox/−). Four weeks later, the ALA-fed mice and control
mice were killed and liver weight/body weight (A) and spleen weight/body weight (B)
were determined. *P < .05.
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Figure 7.
Histochemical analysis of wild-type and hepatocyte-deleted Mfrn1 livers.
Livers from mice fed ALA were harvested at 6 weeks and stained with hematoxylin
and eosin (A) or trichrome (B) in Alb-Cre;Mfrn1+/+. (C) Enlarged image from panel
B. Alb-Cre;Mfrn1flox/+ were stained with hematoxylin and eosin (D) or trichrome (E).
Panel F is an enlarged image from panel E. Alb-Cre;Mfrnlflox/− were stained with
hematoxylin and eosin (G) or trichrome (H). Panel I is an enlarged image from panel
G. Asterisks in the enlarged images of panels F and I denote areas of fibrosis.
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